anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Craniofacial injuries have serious psychosocial sequele and affect quality of life. Many individuals who suffer significant facial disfigurement from injury experience psychological distress and impairment in functioning not limited to the acute phase of injury, but over a longer term period of treatment, recovery, and adjustment. Until recently, treatment of disfiguring craniofacial injuries has been mostly limited to surgical flap procedures, microsurgical tissue transfer, and implantable prostheses. However, these methods can leave conspicuous scars on the face and the donor site, and in the case of implants can lead to complications associated with foreign materials. Autologous fat grafting with minimally invasive cannulas is a procedure that has been used for decades in common plastic surgery practice for facial aesthetic procedures. This technique is also a promising treatment for soft tissue reconstruction after craniofacial trauma because the graft harvest and injection are minimally invasive. The treatment is performed by using a small liposuction cannula to aspirate fat tissue from the donor site, and then re-injecting the fat into the recipient site with specialized injection cannulas. After harvest, and prior to injection, the fat graft is subjected to a mechanical processing step to separate the aqueous layer and concentrate the adipocytes. This often takes the form of centrifugation or filtering.

The main problem with autologous fat grafting is a variable resorption of the graft volume over time. As much as 30-60% of the graft volume can diminish over time. Many variables may influence the behavior of clinical fat grafts, including harvest site, harvest technique, graft preparation, and injection technique.

Concentrating the already present autologous adipose stromal cells within the fat grafts is not expected to increase subject risk levels beyond the risk levels of the application of fat grafts. We are currently approved for the application of fat grafts with concentrated autologous adipose stromal cells \[IRB#10100293\]. This proposal uses an increased concentration of adipose stromal cells compared to the above referenced study; no increase of risk to the subject is anticipated. We hypothesize that fat grafting for facial trauma, facilitated by enhancing graft quality with a higher concentration of endogenous autologous vascular adipose stromal cells in the grafted tissue, will enhance the successful restoration of tissue volume and craniofacial form. The use of a higher concentration of autologous adipose stromal cells may lead to lower fat resorption rates that may be observed in the approved IRB study \[PRO10100293\]. Additionally, we hypothesize that the clinical results using the concentrated autologous stromal vascular cells will be durable and the subject's quality of life scores will be improved compared to subjects who have had fat grafting alone using historical controls.
Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
OBJECTIVES: The purpose of this study was to evaluate the safety and efficacy of autologous fat tissue injection into the knee joint for the treatment of osteoarthritis.
METHODS: We reviewed 165 patients who received an intra-articular injection of autologous fat tissue for knee osteoarthritis. The efficacy of the treatment was evaluated at 1, 3, 6, and 12 months follow-up using the Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Oxford Knee Score (OKS). Patients with knee arthritis were classified as grades I-IV according to the Kellgren-Lawrence scale (K-L). The clinical and demographic information of the patients, NSAIDs or opioid use, and the side effects related to the procedure were recorded.
RESULTS: There were 62 male and 103 female patients. The mean age was 61.28±11.4 years, and the mean BMI was 26.23±4.49. A significant improvement (p<0.001) was observed in VAS, WOMAC, and OKS values of patients with K-L grade I-III osteoarthritis. Patients with K-L grade IV osteoarthritis showed no statistically significant improvement. No serious complications were observed in the patients. In addition, a statistically significant decrease was found in the daily doses of paracetamol/tramadol and in the number of patients who continued to use NSAIDs after 12 months of follow-up.
CONCLUSION: The results of the study suggest that minimally manipulated autologous fat tissue injections are effective and safe treatment methods for patients with grade I-III knee osteoarthritis. The results may not be satisfactory in severe osteoarthritis due to the limited capabilities.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely, to psychiatry, and deals with treatment of depression, resistant to psychopharmacotherapy. For this purpose realised is fasting-diet therapy. Duration of fasting period is determined by dynamics of ketone level in patient's urine. Ketone level is determined daily, diagram of level dynamics is built, development of second peak is an indicator for finishing fasting period and transition to restoring period of fasting-diet therapy. ^ EFFECT: method ensures increase of treatment efficiency in absence of side effects due to introduction of objective criterion of fasting period end. ^ 1 ex, 1 tbl, 2 dwg
Myocardial infarction (MI) seriously threatens the health of elderly people, and reducing myocardial injury is of great significance for the treatment of MI. LncRNA-TTN-AS1 shows protective effects on cardiomyocyte injury, while the role of TTN-AS1 in MI remains unknown. CCK8, flow cytometry, and JC-1 staining assessed cell viability, apoptosis and mitochondrial membrane potential (MMP), respectively. Cellular reactive oxygen species (ROS) and secreted lactate dehydrogenase (LDH) levels were measured. The interactions between ELF5, TTN-AS1, PCBP2 and CDK6 were explored using ChIP, luciferase reporter assay, RIP, and pull-down. The severity of MI in mice was evaluated using TTC, H&E, and TUNEL staining. The data revealed that OGD/R significantly induced ROS, mitochondrial injury and apoptosis in AC16 cells, while overexpression of ELF5 or TTN-AS1 reversed these phenomena. ELF5 transcriptionally activated TTN-AS1 through binding with its promoter. TTN-AS1 increased CDK6 stability via recruiting PCBP2. CDK6 knockdown abolished the inhibitory effects of TTN-AS1 overexpression on OGD/R-induced myocardial injury. Furthermore, overexpression of TTN-AS1 or ELF5 alleviated MI progression in mice by upregulating CDK6. Collectively, TTN-AS1 transcriptionally regulated by ELF5 alleviated myocardial apoptosis and injury during MI via recruiting PCBP2 to increase CDK6 stability, which shed new lights on exploring new strategies against MI.
OBJECTIVES: I. Compare the objective tumor response rate of patients with stage III or IV melanoma when treated with intratumoral bleomycin with or without electroporation therapy. II. Determine the safety of electroporation therapy in these patients. III. Compare the time to heal with these treatments in these patients. IV. Compare the duration of lesion response with these treatments in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to one of two treatment arms. Arm I: Patients receive bleomycin intratumorally on day 1. Arm II: Patients receive bleomycin intratumorally followed by electroporation therapy intratumorally on day 1. Treatment continues every 4 weeks in the absence of unacceptable toxicity. Patients in arm I with progressive disease after 1 course of treatment may be crossed over to arm II. Patients are followed at 4 and 6 months after final treatment.

PROJECTED ACCRUAL: A total of 20 patients (10 per treatment arm) will be accrued for this study.
Healthy volunteers with no sign of internal disease. Age 18-50, both women and men.
Aging is associated with deficiencies in the prefrontal cortex, including working memory impairment, and compromised integrity of neuronal dendrites. The role of Protein Kinase C(PKC) in age-related prefrontal cortical impairments had not been previously determined. The inventors provides evidence that PKC activity is associated with prefrontal cortical dysfunction in aging. The inventors provide methods of reversing the effects of prefrontal cortical decline, improving cognition, and improving working memory in aged subjects by providing a phenanthridinium alkaloid or closely related compound to the subject. The inventors found chelerythrine reversed working memory impairments in aged rats and enhanced working memory in aged rhesus monkeys. Improvement correlated with age, with older monkeys demonstrating a greater degree of improvement following PKC inhibition. The inventors findings indicate that PKC is dysregulated in aged subjects and that PKC inhibitors may be used to treatment improve cognition in the elderly.
The invention relates to a new preparation formulation using high-quality pure paper (or containing medicament) to be made into paper patch and particular applied to local oral cavity. The paper patch is formed by making a soft paperboard by 36-48 layers of paper with 0.15-0.2cm and cutting into the shape of rectangular strip with 3cm length and 1.2cm width. The paper patch has stronger absorbency, adsorbability, adsorption polymerization (adsorbing and polymerizing antibiosis substances of saliva and gingival crevicular fluid), and hemostatic and protective properties, can getter bacterium, endotoxin and inflammatory cytokines, as well as suppuration smell and bacterial plaque. The new preparation formulation has the functions of eliminating inflammation to stop pain, and stopping bleeding and diminishing swelling, further can protect the mucosa barrier of the oral cavity so as to be free from of invasion of bacterium and endotoxin on the blood and cause cardio-cerebrovascular diseases. Shown by initial trial, the new preparation formulation has tremendous curative effect on toothache. The medicament-containing paper patch can have the effect of being fast in action and high in curative effect, reducing adverse reaction and improving safety. When being used in hypogloeeis, the paper patch provides a novel hypogloeeis paper patch for hypogloeeis administration for treating intracorporal disease, especially cardiovascular disease and respiratory system disease. The product has no adverse effect, is absolutely safe, simple to administrate, no smell and stimulation, and good mouthfeeling, and can be popular with any people. The product is easy to produce, rich in raw materials and low in cost.
BACKGROUND: Migraine is among the most prevalent and burdensome neurological disorders in the United States based on disability-adjusted life years. Cortical spreading depolarization (SD) is the most likely electrophysiological cause of migraine aura and may be linked to trigeminal nociception. We previously demonstrated, using a minimally invasive optogenetic approach of SD induction (opto-SD), that opto-SD triggers acute periorbital mechanical allodynia that is reversed by 5HT1B/1D receptor agonists, supporting SD-induced activation of migraine-relevant trigeminal pain pathways in mice. Recent data highlight hypothalamic neural circuits in migraine, and SD may activate hypothalamic neurons. Furthermore, neuroanatomical, electrophysiological, and behavioral data suggest a homeostatic analgesic function of hypothalamic neuropeptide hormone, oxytocin. We, therefore, examined the role of hypothalamic paraventricular nucleus (PVN) and oxytocinergic (OXT) signaling in opto-SD-induced trigeminal pain behavior.
METHODS: We induced a single opto-SD in adult male and female Thy1-ChR2-YFP transgenic mice and quantified fos immunolabeling in the PVN and supraoptic nucleus (SON) compared with sham controls. Oxytocin expression was also measured in fos-positive neurons in the PVN. Periorbital mechanical allodynia was tested after treatment with selective OXT receptor antagonist L-368,899 (5 to 25 mg/kg i.p.) or vehicle at 1, 2, and 4 h after opto-SD or sham stimulation using von Frey monofilaments.
RESULTS: Opto-SD significantly increased the number of fos immunoreactive cells in the PVN and SON as compared to sham stimulation (p < 0.001, p = 0.018, respectively). A subpopulation of fos-positive neurons also stained positive for oxytocin. Opto-SD evoked periorbital mechanical allodynia 1 h after SD (p = 0.001 vs. sham), which recovered quickly within 2 h (p = 0.638). OXT receptor antagonist L-368,899 dose-dependently prolonged SD-induced periorbital allodynia (p < 0.001). L-368,899 did not affect mechanical thresholds in the absence of opto-SD.
CONCLUSIONS: These data support an SD-induced activation of PVN neurons and a role for endogenous OXT in alleviating acute SD-induced trigeminal allodynia by shortening its duration.
This present invention provides a class of gene transfection reagents, which have a structure containing a nucleic acid binding domain and sugar targeting domain. The compounds are easy to synthesize and formulate. The formulated compound associates with DNA to form small particles with nearly neutral surface charge. The sugar domain plays a role as a tissue target ligand located on the surface of the nucleic acid complex, which promotes the receptor-mediated gene transfection. In the presence of proteins, these DNA complexes do not bind with proteins to form precipitates. The complexes are also stable when stored at 4° C. for a long time.
Risk Summary

In animal reproduction studies, intravenous administration of clofarabine to pregnant rats and rabbits during organogenesis at doses approximately 0.2- to 1-times the maximum recommended human dose of 52 mg/m2 based on body surface area (BSA) resulted in embryo-fetal mortality, alterations to growth, and structural abnormalities (see Data). Advise pregnant women of the potential risk to a fetus. There are no available data on clofarabine use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Clofarabine should be used during pregnancy only if the potential benefits to the mother outweigh the potential risks, including those to the fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal data

Intravenous administration of clofarabine to pregnant rats during organogenesis (gestation days [GD] 7-17) at doses of 1, 3 or 9 mg/kg/day (equivalent to 6, 18, 54 mg/m2/day) resulted in maternal toxicities at the 9 mg/kg dose, as indicated by reduced body weights and food consumption. Developmental toxicity (i.e., reduced fetal body weights and increased postimplantation loss) and increased incidences of external, soft tissue, and skeletal malformations and variations (including retarded ossification) were observed at 9 mg/kg/day (54 mg/m2; approximately equivalent to the recommended human dose based on BSA). Altered ossification patterns (extra metacarpal or metatarsal ossification) were observed in single fetuses at lower doses of clofarabine (1 and 3 mg/kg/day; 0.1- and 0.3-times the recommended human dose based on BSA).

When clofarabine was administered intravenously to pregnant rabbits during organogenesis (GD 6-18) at doses of 0.1, 0.3, or 1 mg/kg/day (equivalent to 1.2, 3.6, 12 mg/m2/day), developmental toxicity (i.e., reduced fetal body weights and increased postimplantation loss) and increased incidences of external, soft tissue, and skeletal malformations and variations (including retarded ossification) were observed at the 1 mg/kg/day dose (12 mg/m2; 0.2-times the recommended human dose based on BSA). Alterations in ossification patterns (increase in the average numbers of ossified thoracic vertebrae and rib pairs, and reduction in the average number of forepaw metacarpals) and abdominal wall defect were observed at 0.3 mg/kg/day (3.6 mg/m2; 0.1-times the recommended human dose based on BSA).
Medical advances prolonging life have led to more permanent pacemaker implants. When pacemaker implantation (PMI) is commonly caused by sick sinus syndrome or conduction disorders, predicting PMI is challenging, as patients often experience related symptoms. This study was designed to create a deep learning model (DLM) for predicting future PMI from ECG data and assess its ability to predict future cardiovascular events. In this study, a DLM was trained on a dataset of 158,471 ECGs from 42,903 academic medical center patients, with additional validation involving 25,640 medical center patients and 26,538 community hospital patients. Primary analysis focused on predicting PMI within 90 days, while all-cause mortality, cardiovascular disease (CVD) mortality, and the development of various cardiovascular conditions were addressed with secondary analysis. The study's raw ECG DLM achieved area under the curve (AUC) values of 0.870, 0.878, and 0.883 for PMI prediction within 30, 60, and 90 days, respectively, along with sensitivities exceeding 82.0% and specificities over 81.9% in the internal validation. Significant ECG features included the PR interval, corrected QT interval, heart rate, QRS duration, P-wave axis, T-wave axis, and QRS complex axis. The AI-predicted PMI group had higher risks of PMI after 90 days (hazard ratio [HR]: 7.49, 95% CI: 5.40-10.39), all-cause mortality (HR: 1.91, 95% CI: 1.74-2.10), CVD mortality (HR: 3.53, 95% CI: 2.73-4.57), and new-onset adverse cardiovascular events. External validation confirmed the model's accuracy. Through ECG analyses, our AI DLM can alert clinicians and patients to the possibility of future PMI and related mortality and cardiovascular risks, aiding in timely patient intervention.
NEW MATERIAL:A peptide capable of specifically binding to the antibody having specificity to adult T-cell leukemia-related antigen (ATLA), of formula I (A is peptide fragment of e.g. formula II where 6-50 amino acids forms a sequence; Y is OH or amino group). USE:Reagents for assaying anti-ATLA antibody, adsorbents for anti-ATLA antibody, therapeutic agents for adult T-cell leukemia virus infectious diseases. PREPARATION:For example, using as a solid phase carrier a granular resin consisting of e.g. a styrene-divinylbenzene copolymer prepared by solid phase synthesis, amino acids with their alpha-amino groups and side chain functional groups protected are successively bound starting from the C-terminal according to the amino acid sequence of the objective peptide to synthesize a peptide resin. Thence, this peptide is eliminated from the resin using e.g. trifluoroacetic acid and all of the protected groups are removed, and the product is then purified through the reverse-phase high performance liquid chromatography, thus obtaining the objective peptide of the formula I.
A system (100) and method for providing guidance in an ultrasound imaging procedure involves presenting graphical user interface (131) elements overlaid onto an external image of the subject's body. The system includes at least one camera (137) for capturing the external image of the subject. The system may utilize trained artificial neural network(s) (150) to identify locations in the external image that correspond to scanning zones of a scanning protocol. A probe (112) placement marker is overlaid at each identified location to indicate the position of the probe's face onto the subject's body for acquiring a target view of the internal anatomy. Additional graphical elements may be presented via the guidance interface (133) and results findings may optionally be overlaid onto the external image of the subject at the completion of the scan. In embodiments herein, imaging guidance is provided solely via the external images of the subject without displaying the ultrasound image data.
The present disclosure relates to the field of biology, in particular, to an anti-CLD18A2 VHH. The present disclosure provides an anti-CLD18A2 VHH. A complementarity determining region (CDR) of the anti-CLD18A2 VHH includes CDR1-CDR3 having amino acid sequences as shown below: CDR1 having an amino acid sequence represented by one of SEQ ID NO. 4-11, CDR2 having an amino acid sequence represented by one of SEQ ID NO. 19-26, and CDR3 having an amino acid sequence represented by one of SEQ ID NO.33-39. The anti-CLD18A2 VHH of the present disclosure can specifically bind to the epitope on CLD18A2, and the corresponding fusion protein thereof has good specificity and affinity for CLD18A2, and has a noticeable tumor suppression effect.
PURPOSE: A pharmaceutical formulation is provided to prevent metabolism interfering function between drugs and side effects with different release time. CONSTITUTION: A pharmaceutical formulation contains immediate release compartment and extended release compartment. The immediate release compartment contains a pharmacologically active olmesartan medoxomil or its pharmaceutically acceptable salt. The extended release compartment contains a pharmacologically active azelnidipine or its pharmaceutically active salt. 85% or more olmesartan medoxomil is released within one hour after releasing olmesartan medoxomil. The azelnidipine is released one to four hours after releasing the olmesartan medoxomil.
A 3+3 dose de-escalation design for three dose levels of lenvatinib combined with cetuximab will be used. A DLT will be defined as any toxicities of grade 3 or higher (per CTCAE v4 criteria) felt to be possibly, probably, or definitely related to lenvatinib, as well as grade 4 toxcities related to cetuximab, which occurs within 28 days following the first dose of lenvatinib in combination with cetuximab.
Flavonoid natural products are emerging as a promising approach for treating Ulcerative Colitis (UC) due to their natural origin and minimal toxicity. This study investigates the effects of Neohesperidin (NEO), a natural flavonoid, on Dextran Sodium Sulfate (DSS)-induced UC in mice, focusing on the underlying molecular mechanisms. Early intervention with NEO (25 and 50 mg/kg) mitigated colon shortening, restored damaged barrier proteins, and significantly reduced the inflammatory cytokine levels. Moreover, NEO inhibited the MAPK/NF-κB signaling pathway and enhanced the levels of intestinal barrier proteins (Claudin-3 and ZO-1). Additionally, NEO increased beneficial intestinal probiotics (S24-7 and Lactobacillaceae) while reducing harmful bacteria (Erysipelotrichi, Enterobacteriaceae). Fecal microbial transplantation (FMT) results demonstrated that NEO (50 mg/kg) markedly improved UC symptoms. In conclusion, early NEO intervention may alleviate DSS-induced UC by inhibiting inflammatory responses, preserving intestinal barrier integrity and modulating gut microbiota.
Controversies regarding the risk factors affecting direct-to-implant (DTI) immediate breast reconstruction still exist. This study aimed to evaluate the risk factors for severe complications in DTI breast reconstruction and explore potential salvage management strategies. We conducted a retrospective review of 238 patients (240 breasts) who underwent DTI immediate breast reconstruction between 2011 and 2020. Multivariate logistic regression analyses were used to identify the risk factors predicting severe complications. Seventeen (7.08%) reconstructed breasts experienced severe complications, of which only 5 were successfully salvaged through surgical revision, while the others failed and resulted in implant removal. Multivariate analyses demonstrated that mesh use [odds ratio (OR) = 4.054, 95% confidence interval: 1.376-11.945, P = .011] and post-mastectomy radiotherapy (odds ratio = 4.383, 95% confidence interval 1.142-16.819, P = .031) were independent predictors of severe complications. Mesh use and post-mastectomy radiotherapy for breast reconstruction increase the risk of severe complications. Despite positive surgical treatment, the successful salvage rate was poor.